Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DHEP · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| DHEP | BEHAVIORAL | - |
Inclusion Criteria: * Insured under Medicaid (SSI) or dual enrolled under Medicaid and Medicare for at least one year * Diagnosed type 1 or type 2 diabetes for at least 1 year (\>1 inpatient or \>2 outpatients visits with ICD-9 codes 250.00-250.9x, or prescriptions for insulin and/or oral hyperglyc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
DHEP is an investigational program being studied for use in diabetes. It is designed to improve the health of people with diabetes, as evaluated in a Phase 3 clinical trial. The program is still in clinical development and has not been approved by regulatory authorities.
DHEP is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research to evaluate the program's effects in patients with diabetes.
DHEP is in Phase 3 clinical development. A Phase 3 trial has been completed, which is the final stage of testing before potential regulatory submission. However, DHEP remains investigational and is not yet approved for use.
DHEP has one completed Phase 3 clinical trial registered as NCT00291590, titled "Diabetes Health Enhancement Program to Improve Health of People With Diabetes." The trial enrolled 146 participants in the United States, with a minimum age of 40 years, and included both sexes.
The completed Phase 3 trial for DHEP was randomized but did not use a control group, meaning it was an uncontrolled study. The trial was not double-blind, and it enrolled 146 participants with diabetes to evaluate the program's health outcomes.